Alcohol withdrawal syndrome in critically ill patients
- 1 December 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 77 (6) , 938-943
Abstract
BACKGROUND Approximately 18% to 25% of patients with alcohol use disorders admitted to the hospital develop alcohol withdrawal syndrome (AWS). Symptom-triggered dosing of benzodiazepines (BZDs) seems to lead to shorter courses of treatment, lower cumulative BZD dose, and more rapid control of symptoms in non–critically ill patients. This study compares the outcomes of critically ill patients with AWS when treated using a protocolized, symptom-triggered, dose escalation approach versus a nonprotocolized approach. METHODS This is a retrospective pre-post study of patients 18 years or older with AWS admitted to an intensive care unit (ICU). The preintervention cohort (PRE) was admitted between February 2008 and February 2010. The postintervention cohort (POST) was admitted between February 2012 and January 2013. The PRE patients were treated by physician preference and compared with POST patients who were given escalating doses of BZDs and/or phenobarbital according to an AWS protocol, titrating to light sedations (Richmond Agitation Sedation Scale score of 0 to −2). RESULTS There were 135 episodes of AWS in 132 critically ill patients. POST patients (n = 75) were younger (50.7 [13.8] years vs. 55.7 [8.7] years, p = 0.03) than PRE patients (n = 60). Sequential Organ Failure Assessment (SOFA) scores were higher in the PRE group (6.1 [3.7] vs. 3.9 [2.9], p = 0.0004). There was a significant decrease in mean ICU length of stay from 9.6 (10.5) days to 5.2 (6.4) days (p = 0.0004) in the POST group. The POST group also had significantly fewer ventilator days (5.6 [13.9] days vs. 1.31 [5.6] days, p < 0.0001) as well as a significant decrease in BZD use (319 [1,084] mg vs. 93 [171] mg, p = 0.002). There were significant differences between the two cohorts with respect to the need for continuous sedation (p < 0.001), duration of sedation (p < 0.001), and intubation secondary to AWS (p < 0.001). In all of these outcomes, the POST cohort had a notably lower frequency of occurrence. CONCLUSION A protocolized treatment approach of AWS in critically ill patients involving symptom-triggered, dose escalations of diazepam and phenobarbital may lead to a decreased ICU length of stay, decreased time spent on mechanical ventilation, and decreased BZD requirements. LEVEL OF EVIDENCE Epidemiologic study, level III; therapeutic study, level IV.Keywords
This publication has 22 references indexed in Scilit:
- A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawalThe American Journal of Emergency Medicine, 2011
- Alcohol-Use Disorders in the Critically Ill PatientChest, 2010
- Inappropriate Use of Symptom-Triggered Therapy for Alcohol Withdrawal in the General HospitalMayo Clinic Proceedings, 2008
- A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens*Critical Care Medicine, 2007
- False Positives on the Clinical Institute Withdrawal Assessment for Alcohol—Revised: Is This Scale Appropriate for Use in the Medically Ill?Psychosomatics, 2004
- The Richmond Agitation–Sedation Scale: Validity and Reliability in Adult Intensive Care Unit PatientsAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Individualized Treatment for Alcohol WithdrawalJAMA, 1994
- Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA‐Ar)British Journal of Addiction, 1989
- Intravenous phenobarbital for alcohol withdrawal and convulsionsAnnals of Emergency Medicine, 1987
- COMPARISON OF THE ACTIONS OF DIAZEPAM AND LORAZEPAMBritish Journal of Anaesthesia, 1979